Kyverna Therapeutics (NASDAQ:KYTX) Shares Down 6.7% - Here's What Happened

Key Points

• Shares fell 6.7% on Friday to about $8.94 with ~304,427 shares traded, a 59% drop from the stock's average daily volume, after closing the prior session at $9.58.
• Analyst coverage is mixed — four Buys and one Sell — giving Kyverna a consensus rating of "Moderate Buy" and a consensus target price of $28.67, while firms including Morgan Stanley and Wells Fargo have set $33 targets and one firm recently cut its rating to Sell.
• Kyverna is a clinical‑stage biotech (market cap ~$542M) developing engineered regulatory T‑cell therapies, reported Q1 EPS of ($0.80) in line with estimates, and institutional investors hold about 18% of the stock with several funds adding positions recently.

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) dropped 6.7% during trading on Friday . The company traded as low as $8.93 and last traded at $8.9390. Approximately 304,427 shares were traded during mid-day trading, a decline of 59% from the average daily volume of 742,747 shares. The stock had previously closed at $9.58.

Analysts Set New Price Targets

Several equities analysts recently issued reports on KYTX shares. Wall Street Zen cut shares of Kyverna Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 21st. Morgan Stanley set a $33.00 price target on shares of Kyverna Therapeutics in a report on Monday, December 15th. Wells Fargo & Company raised their price target on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the company an "overweight" rating in a report on Tuesday, December 16th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kyverna Therapeutics in a report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Kyverna Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $28.67.

Kyverna Therapeutics Stock Performance

The stock has a market cap of $542.15 million, a P/E ratio of -2.46 and a beta of 2.62. The company has a debt-to-equity ratio of 0.11, a current ratio of 7.75 and a quick ratio of 7.75. The firm's 50-day moving average price is $8.24 and its 200-day moving average price is $7.86.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.80) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.80). Sell-side analysts expect that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its stake in Kyverna Therapeutics by 16.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,762,617 shares of the company's stock valued at $16,569,000 after acquiring an additional 250,418 shares during the period. Adage Capital Partners GP L.L.C. purchased a new position in shares of Kyverna Therapeutics during the 4th quarter valued at approximately $15,667,000. AIGH Capital Management LLC purchased a new position in shares of Kyverna Therapeutics during the 4th quarter valued at approximately $14,100,000. Vanguard Group Inc. increased its holdings in shares of Kyverna Therapeutics by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company's stock valued at $7,936,000 after purchasing an additional 9,858 shares in the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Kyverna Therapeutics during the 4th quarter valued at approximately $9,220,000. 18.08% of the stock is owned by institutional investors and hedge funds.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.